Corbett Accel taps Cooper-Broski as new EVP,CMO

Share this article:

Omnicomm unit Corbett Accel Healthcare Group has hired 30-year advertising veteran Elisa Cooper-Broski, to serve as its new EVP and chief marketing officer (CMO).

In her new role, Cooper-Broski will direct Corbett Accel's business development strategy and lead brand-building efforts for the company's five business units in conjunction with the business unit leaders.

Cooper-Broski will be based in Corbett Accel's New York office and will report directly to CEO Scott Cotherman.

“The CMO role is relatively unknown in pharmaceutical advertising,” said Cotherman. "We are one of the first to identify the value a chief marketing officer brings to an organization. Elisa Cooper-Broski's extensive knowledge of the pharmaceutical industry, along with her multi-faceted experience, will be invaluable as we advance our integrated business development strategy."

Cooper-Broski previous experience includes work with GSW New York's presence, Saatchi & Saatchi Healthcare (formerly Klemtner Advertising) CommonHealth USA and NCI Advertising (formerly Rolf Werner Rosenthal).

Prior to joining Corbett Accel, Cooper-Broski was president and chief branding officer for Bruce Leeb & Company, a privately held healthcare advertising agency.

“In this environment, my role as CMO will strengthen the overall impact of Corbett Accel and its business units in the pharmaceutical industry as a communications company that delivers visionary results with substantial and beneficial outcomes” said Cooper-Broski in a statement.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.